JAZZ

Jazz Pharmaceuticals Plc - 10-Q Summary (Q3 2008)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2008. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology and psychiatry. Its primary marketed products are Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder and social anxiety disorder. The company is currently developing JZP-6 (sodium oxybate) for fibromyalgia.

Key Financial Metrics

Note: Senior Secured Notes balance includes $91.6 million held by related parties. Line of credit balance is $3.3 million.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 4% to $47.9 million for the nine months ended September 30, 2008, compared to $49.8 million in the prior year period. This was driven by a 92% drop in contract revenues due to the absence of a $7.5 million milestone payment received in 2007, partially offset by a 18% increase in product sales.
• Product Sales Growth: Product sales increased 18% to $45.8 million, primarily due to Xyrem sales growth ($38.0 million vs. $27.9 million) and the launch of Luvox CR ($2.7 million). Sales of Antizol and Cystadane were eliminated following the sale of rights to these products.
• Increased Expenses: Selling, general, and administrative (SG&A) expenses surged 80% to $91.2 million, largely due to the Luvox CR launch and sales force expansion. Research and development (R&D) expenses increased 12% to $55.3 million.
• Inventory Charge: The company recorded a $3.0 million charge to cost of product sales for excess Luvox CR inventory and cancelled production orders.
• Gain on Sale: A $3.9 million gain was recognized from the sale of Antizol and Antizol-Vet rights in August 2008.

Guidance, Outlook, and Risks

• Liquidity Concerns: Management states the company will need to raise additional funds by early 2009 to support operations. Failure to secure funding could require significant scaling back of operations, headcount reductions, or discontinuation of activities.
• Luvox CR Performance: Demand for Luvox CR has been lower than anticipated. In November 2008, the company implemented a workforce reduction of 67 employees (including 62 in the sales force) and expects to record a $1.6 million charge in Q4 2008.
• JZP-6 Clinical Trial: The company's ability to raise capital depends significantly on preliminary data from the first Phase III pivotal clinical trial of JZP-6 for fibromyalgia, expected in Q4 2008.
• Financing Constraints: The Committed Equity Financing Facility (CEFF) with Kingsbridge Capital is currently inaccessible because the company's stock price is trading below the $4.50 threshold required to draw funds.
• Debt Covenants: The company has $120 million in senior secured notes. If annualized net product sales fall below $100 million and a generic Xyrem is approved, the company may be required to redeem up to $30 million of notes. Additionally, a restricted cash balance of 15% of outstanding notes may be required after Q1 2009.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $49.9 million cash balance against the projected burn rate and the timeline for raising capital in early 2009.
• Luvox CR Sell-Through: Monitor prescription data to determine if revenue recognition can shift from "sell-through" to "sell-in" basis, which would impact future revenue volatility.
• JZP-6 Trial Data: Await Q4 2008 preliminary data from the Phase III fibromyalgia trial, as this is a critical determinant for future financing and valuation.
• Debt Compliance: Review compliance with senior secured note covenants, specifically the potential requirement to maintain a restricted cash balance starting Q2 2009.
• Stock Price Threshold: Monitor the common stock price relative to the $4.50 threshold required to access the $75 million CEFF facility.